Walnut Lipid Profile Randomized Trial: What the Evidence Says

Quick Answer

Walnut Lipid Profile Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• One of its principal risk factors is dyslipidemia, a metabolic disorder defined by elevated plasma levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo-B), alongside reduced concentrations of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (Apo-A1) (Arvanitis and Lowenstein ). [Mashayekhi Ghazal (2026); evidence level 1]
• Likewise, Hwang et al.  found that 16 weeks of walnut supplementation increased HDL-C levels but did not affect other lipid markers in individuals with metabolic syndrome. [Mashayekhi Ghazal (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For walnut lipid profile randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Mashayekhi Ghazal (2026). Effects of Walnut Consumption on Blood Lipid Profile and Apolipoproteins in Adults: A GRADE ‐Assessed Systematic Review and Dose–Response Meta‐Analysis of 49 Randomized Controlled Trials. DOI: 10.1002/fsn3.71526. PMCID: PMC12887447. PMID: 41676011. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12887447/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.